SOPHiA GENETICS Reports Third Quarter 2024 Financial Results
Clinical growth reaccelerates with record analysis volume; Cash burn improves 39%
SOPHiA GENETICS (NASDAQ: SOPH), a leader in data-driven medicine, disclosed its third-quarter financial results, showcasing notable progress in key areas.
Financial Performance Highlights
Revenue Trends
During the third quarter of 2024, SOPHiA GENETICS reported revenues of $15.9 million, reflecting a slight decrease of 2.8% year-over-year. However, this decline is seen against the backdrop of robust growth and market conditions.
Margin Analysis
Gross margins were impressive, recorded at 67.2% on a reported basis and reaching 73.1% when adjusted. This is an increase from 69.1% and 72.5% respectively from the previous year, signaling operational efficiency improvements.
Operating Loss and Cash Burn
The operating loss stood at $15.4 million on a reported basis and $10.6 million adjusted, representing year-over-year improvements of 7.1% and 10.4% respectively. The company also significantly reduced cash burn to $9.6 million, an impressive 39.1% decrease from last year.
Future Guidance Remains Positive
SOPHiA GENETICS has reiterated its full-year outlook, projecting revenue between $65 million and $67 million, targeting adjusted gross margins between 72.0% to 72.5%, and forecasted adjusted operating losses ranging from $45 million to $50 million.
Operational Achievements in Q3 2024
Clinical Growth and Customer Acquisition
The record analysis volume played a pivotal role in driving clinical growth across key markets, with a 16% year-over-year increase in analysis volume. However, the company experienced expected reductions in the BioPharma sector.
New Customers and Strategic Expansion
Further enhancing its momentum, SOPHiA GENETICS onboarded 20 new clients in the third quarter, with significant customer signings in the United States, the United Kingdom, and Brazil. These developments are pivotal for the company’s growth strategy.
Innovations in Product Offerings
Dr. Jurgi Camblong, CEO, expressed enthusiasm over the introduction of the new Liquid Biopsy application MSK ACCESS™, which has gained 18 new users post-launch, alongside the Solid Tumor testing application MSK-IMPACT™. This signifies increased interest and investment opportunities in the Biopharma sector.
2024 Financial Outlook and Strategic Focus
Looking ahead, SOPHiA GENETICS remains committed to reaching adjusted operating profitability within the next two years, underpinned by its strategic focus on enhancing operational excellence and sustainable growth. The management believes that the current cash position and resources will support this objective.
Frequently Asked Questions
What factors contributed to SOPHiA GENETICS' revenue decline in Q3 2024?
The decrease stems primarily from anticipated softness in the BioPharma sector, offset by growth in clinical analysis volumes.
How did the company manage to reduce cash burn?
SOPHiA GENETICS implemented cost management measures, leading to a 39.1% reduction in cash burn compared to the previous year.
What is the projected revenue for the full year?
The company expects full-year revenue to be between $65 million and $67 million.
How many new clients were signed in Q3 2024?
During Q3 2024, SOPHiA GENETICS signed 20 new clients, contributing positively to its growth trajectory.
What innovations are expected from SOPHiA GENETICS moving forward?
Future innovations include the continued adoption of its Liquid Biopsy and Solid Tumor testing applications, aimed at improving global health outcomes.
